Peer-reviewed veterinary case report
How heart drugs affect angiotensin peptides in cats with heart disease
By Huh, Terry et al.·Published in Journal of veterinary internal medicine·2021·Department of Clinical Sciences and Advanced Medicine, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Effect of angiotensin receptor blockers and angiotensin-converting enzyme 2 on plasma equilibrium angiotensin peptide concentrations in cats with heart disease.
- Species:
- cat
Plain-English summary
A group of six cats with heart disease (cardiomyopathy) had their blood tested to see how certain medications affected their hormone levels. The cats were given a medication called telmisartan for two weeks, which helped change the balance of specific hormones in their blood. While there were no major differences between the sick cats and healthy cats, the sick cats showed higher levels of a beneficial hormone called Ang1-7 after treatment. This suggests that using angiotensin receptor blockers like telmisartan may help improve hormone balance in cats with heart disease.
People also search for: cat heart disease treatment · telmisartan for cats · angiotensin receptor blockers in cats
Abstract
BACKGROUND: Little is known about the effect of renin angiotensin aldosterone system-inhibiting (RAASi) drugs on alternative angiotensin peptides (APs) such as angiotensin 1-7 (Ang1-7), which are mediated by angiotensin-converting enzyme 2 (ACE2). HYPOTHESIS/OBJECTIVES: Angiotensin receptor blockers (ARBs) would alter balance of APs and differences would be magnified in vitro by incubation of plasma samples with recombinant human ACE2 (rhACE2). ANIMALS: Six cats with cardiomyopathy (CM), 8 healthy cats. METHODS: Prospective open label trial. Plasma equilibrium concentrations of APs were measured in healthy cats as well as in CM cats that first received no RAASi drugs (CM) and then after 14 days of PO telmisartan (CM). Plasma APs also were measured after in vitro incubation with rhACE2. RESULTS: No significant differences were found between healthy and CMgroups. Concentrations of several APs, including angiotensin I (AT1) and angiotensin II (AT2) were significantly different between CMand CMgroups. Incubation with rhACE2 decreased AT1 and AT2 in both groups. The geometric mean concentration of Ang1-7 was significantly higher in CM(4.9 pg/mL; 95% confidence interval [CI], 3.7-6.4 pg/mL) vs CM(3.2 pg/mL; 95% CI, 2.2-4.7 pg/mL; P = .01) and in CM + ACE2 (5.0 pg/mL; 95% CI, 3.9-6.4 pg/mL) vs CM + ACE2 (3.0 pg/mL; 95% CI, 1.7-5.5 pg/mL; P = .01). The most favorable theoretical AP profile that maximized Ang1-7 and other alternative APs was CM + ACE2. CONCLUSIONS AND CLINICAL IMPORTANCE: Balance between traditional and alternative APs can be favorably shifted using ARBs and in vitro incubation with rhACE2. These data shed light on new AP-targeting strategies in cats with CM.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/33135833/